On May 21, 2024, Invivyd, Inc., a biopharmaceutical company, held its Annual Meeting of Stockholders where seven directors were elected for a one-year term. The elected directors include Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Following the meeting, Invivyd issued a press release announcing the election of two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, who will serve as Chairpersons of the Compensation and Audit Committees, respectively. The company expressed its enthusiasm for the expertise the new directors will bring during a period of...Show More

On May 21, 2024, Invivyd, Inc., a biopharmaceutical company, held its Annual Meeting of Stockholders where seven directors were elected for a one-year term. The elected directors include Tamsin Berry, Sara Cotter, Marc Elia, Srishti Gupta, M.D., Christine Lindenboom, Terrance McGuire, and Kevin McLaughlin. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Following the meeting, Invivyd issued a press release announcing the election of two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, who will serve as Chairpersons of the Compensation and Audit Committees, respectively. The company expressed its enthusiasm for the expertise the new directors will bring during a period of growth, particularly as Invivyd commercializes its first product and advances its proprietary tools for variant analysis and predictive modeling. The press release also highlighted the recent emergency use authorization (EUA) granted by the U.S. FDA for Invivyd's monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals, marking a significant milestone for the company.